Negative Feedback Regulation of the ERK1/2 MAPK Pathway

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2016 Jun 26

PMID 27342992

Citations 245

Authors

David Lake

Sonia A L Correa

Jurgen Muller

Affiliations

Soon will be listed here.

Abstract

The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to environmental circumstances, the pathway must be integrated into the overall signalling activity of the cell. Multiple mechanisms have evolved to perform this role. In this review, we will focus on negative feedback mechanisms and examine how they shape ERK1/2 MAPK signalling. We will first discuss the extensive number of negative feedback loops targeting the different components of the ERK1/2 MAPK cascade, specifically the direct posttranslational modification of pathway components by downstream protein kinases and the induction of de novo gene synthesis of specific pathway inhibitors. We will then evaluate how negative feedback modulates the spatiotemporal signalling dynamics of the ERK1/2 pathway regarding signalling amplitude and duration as well as subcellular localisation. Aberrant ERK1/2 activation results in deregulated proliferation and malignant transformation in model systems and is commonly observed in human tumours. Inhibition of the ERK1/2 pathway thus represents an attractive target for the treatment of malignant tumours with increased ERK1/2 activity. We will, therefore, discuss the effect of ERK1/2 MAPK feedback regulation on cancer treatment and how it contributes to reduced clinical efficacy of therapeutic agents and the development of drug resistance.

Citing Articles

Evaluation of information flows in the RAS-MAPK system using transfer entropy measurements.

Umeki N, Kabashima Y, Sako Y Elife. 2025; 14.

PMID: 40047537 PMC: 11884788. DOI: 10.7554/eLife.104432.

Matrix stiffening induces hepatocyte functional impairment and DNA damage via the Piezo1‒ERK1/2 signaling pathway.

Fan Y, An C, Wang Z, Luo J, Wang W, Luo Q J Physiol Biochem. 2025; .

PMID: 39994097 DOI: 10.1007/s13105-025-01070-1.

Immediate early splicing controls translation in activated T-cells and is mediated by hnRNPC2 phosphorylation.

Drozdz M, Zuvanov L, Sasikumar G, Bose D, Bruening F, Robles M EMBO J. 2025; .

PMID: 39948410 DOI: 10.1038/s44318-025-00374-8.

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.

Al-Noshokaty T, Abdelhamid R, Abdelmaksoud N, Khaled A, Hossam M, Ahmed R Toxicol Rep. 2025; 14:101895.

PMID: 39911322 PMC: 11795145. DOI: 10.1016/j.toxrep.2025.101895.

From bench to bedside: murine models of inherited and sporadic brain arteriovenous malformations.

Ricciardelli A, Genet G, Genet N, McClugage 3rd S, Kan P, Hirschi K Angiogenesis. 2025; 28(2):15.

PMID: 39899215 PMC: 11790818. DOI: 10.1007/s10456-024-09953-5.

References

Coles L, Shaw P . PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene. 2002; 21(14):2236-44. DOI: 10.1038/sj.onc.1205302. View

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

Fuller D, Zhang W . Regulation of lymphocyte development and activation by the LAT family of adapter proteins. Immunol Rev. 2009; 232(1):72-83. PMC: 3646374. DOI: 10.1111/j.1600-065X.2009.00828.x. View

Guy G, Jackson R, Yusoff P, Chow S . Sprouty proteins: modified modulators, matchmakers or missing links?. J Endocrinol. 2009; 203(2):191-202. DOI: 10.1677/JOE-09-0110. View

Ekerot M, Stavridis M, Delavaine L, Mitchell M, Staples C, Owens D . Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J. 2008; 412(2):287-98. PMC: 2474557. DOI: 10.1042/BJ20071512. View

Montagut C, Sharma S, Shioda T, McDermott U, Ulman M, Ulkus L . Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68(12):4853-61. PMC: 2692356. DOI: 10.1158/0008-5472.CAN-07-6787. View

Northwood I, Gonzalez F, Wartmann M, Raden D, Davis R . Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669. J Biol Chem. 1991; 266(23):15266-76. View

Therrien M, Chang H, Solomon N, Karim F, Wassarman D, Rubin G . KSR, a novel protein kinase required for RAS signal transduction. Cell. 1995; 83(6):879-88. DOI: 10.1016/0092-8674(95)90204-x. View

Muller J, Morrison D . Assay of Raf-1 activity. Methods Enzymol. 2001; 345:490-8. DOI: 10.1016/s0076-6879(02)45040-9. View

10.

Casar B, Arozarena I, Sanz-Moreno V, Pinto A, Agudo-Ibanez L, Marais R . Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol Cell Biol. 2008; 29(5):1338-53. PMC: 2643815. DOI: 10.1128/MCB.01359-08. View

11.

Haimov-Kochman R, Ravhon A, Prus D, Greenfield C, Finci-Yeheskel Z, Goldman-Wohl D . Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Mol Hum Reprod. 2005; 11(8):537-42. DOI: 10.1093/molehr/gah203. View

12.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong X . Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012; 287(33):28087-98. PMC: 3431627. DOI: 10.1074/jbc.M112.377218. View

13.

Santos S, Verveer P, Bastiaens P . Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol. 2007; 9(3):324-30. DOI: 10.1038/ncb1543. View

14.

Ravnan M, Matalka M . Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012; 34(7):1474-86. DOI: 10.1016/j.clinthera.2012.06.009. View

15.

Balan V, Leicht D, Zhu J, Balan K, Kaplun A, Singh-Gupta V . Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell. 2006; 17(3):1141-53. PMC: 1382304. DOI: 10.1091/mbc.e04-12-1123. View

16.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

17.

Lavoie H, Therrien M . Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015; 16(5):281-98. DOI: 10.1038/nrm3979. View

18.

Sorkin A, Goh L . Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009; 315(4):683-96. DOI: 10.1016/j.yexcr.2008.07.029. View

19.

Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M . Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997; 17(9):5598-611. PMC: 232408. DOI: 10.1128/MCB.17.9.5598. View

20.

Muller J, Ory S, Copeland T, Piwnica-Worms H, Morrison D . C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell. 2001; 8(5):983-93. DOI: 10.1016/s1097-2765(01)00383-5. View